Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research


Alzheimer's Disease Research
Current Award

Dr. Laurie Erb

Laurie Erb, Ph.D.

The Curators of the University of Missouri
Columbia, MO

Title: Novel Cerebrovascular Regulation in Alzheimer’s Disease
Non-Technical Title: Exploring New Ways to Prevent Brain Cell Death by Increasing Blood Flow

Gary A. Weisman, Ph.D.
University of Missouri

Acknowledgements: This grant is made possible in part by a bequest from the Patsie Lee Clark Trust in memory of James Sterling Clark and Patsie Lee Clark.
Duration: July 1, 2013 - June 30, 2016
Award Type: Standard
Award Amount: $250,000


Alzheimer’s disease (AD) and other neurodegenerative diseases are often preceded by malfunctions in the cerebrovascular system (the brain’s blood vessels), including decreased blood flow in the brain, which leads to hypoxia (low oxygen levels), breakdown of the blood-brain barrier, and, ultimately, to brain atrophy and death. It is known that the endothelial cells that line blood vessels are important regulators of blood flow, and recent work indicates that a protein in endothelial cells (called P2Y2R) is activated under hypoxic conditions, causing relaxation of blood vessels and increases in blood flow. The recent work of Drs. Erb and Weisman with a mouse model of AD shows that global deletion of the P2Y2R (i.e., removal from all cell types) greatly accelerates nerve cell death and the appearance of other classic AD symptoms. Studies in this proposal will investigate whether cerebrovascular changes precede the development of AD symptoms in our AD mouse model, and whether the P2Y2R in endothelial cells, in particular, is important for mediating these events.


The studies of Drs. Erb and Weisman in this proposal will investigate whether cerebrovascular malfunctions, such as increased levels of hypoxia markers and vascular leakage, precede the development of AD symptoms in their AD mouse model. In particular, they will determine whether the P2Y2R in endothelial cells is important for mediating these events.

If endothelial P2Y2R regulation is substantiated in cerebrovascular function and the progression of AD in the mouse model used by Drs. Erb and Weisman, then this basic research study should provide the basis for specific therapeutic interventions to enhance vascular P2Y2R activity in AD patients, and, ultimately, improve cerebrovascular function and nerve cell survival.

Investigator Biography:

Dr. Erb is an Associate Professor of Research in the Biochemistry Department at the University of Missouri, where she completed her doctoral studies. Dr. Erb’s laboratory explores how nucleotide receptors contribute to inflammatory responses after tissue damage or during disease progression. In addition to her BrightFocus award, Dr. Erb is a primary investigator or co-investigator on several National Institute of Health grants that focus on determining the therapeutic potential of nucleotide receptors in treating chronic inflammatory diseases, including Alzheimer’s disease.